Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Descrição
Rucaparib Improves rPFS Vs Physician's Choice in BRCA+ mCRPC
TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC
Prostate cancer and PARP inhibitors: progress and challenges, Journal of Hematology & Oncology
PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies
Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors - ScienceDirect
Advanced Prostate Cancer: Treatment Advances and Future Directions: Trends in Cancer
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - The Lancet
Prostate Cancer Treatment & Management: Approach Considerations, Localized Prostate Cancer, Management of Advanced and Metastatic Disease
ASCO GU 2023: Rucaparib Extends Survival for Metastatic, Castration-Resistant Prostate Cancer
TRITON3 Rucaparib vs Physician's Choice of Single-Agent Therapy in Metastatic Castration-Resistant Prostate Cancer With BRCA or ATM Alterations - The ASCO Post
Rubraca Approved for Metastatic Castration-Resistant Prostate Cancer With BRCA Mutations
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
de
por adulto (o preço varia de acordo com o tamanho do grupo)
